<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04624217</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1701-II-204</org_study_id>
    <nct_id>NCT04624217</nct_id>
  </id_info>
  <brief_title>A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer</brief_title>
  <official_title>A Phase Ib/II Trial of SHR-1701 Combined With Gemcitabine and Albumin Paclitaxel in First-line Treatment of Subjects With Advanced/Metastatic Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy, safety and tolerability of SHR-1701 in&#xD;
      combination with gemcitabine and albumin paclitaxel in first-line treatment of subjects with&#xD;
      advanced/metastatic pancreatic cancer, and determine the RP2D for SHR-1701 in the combined&#xD;
      regimen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 24, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>RP2D</measure>
    <time_frame>Up to week 3</time_frame>
    <description>Recommended Phase 2 Dose of SHR-1701</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>Up to approximately 6 months</time_frame>
    <description>Objective Response Rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinically significant toxicity</measure>
    <time_frame>Up to week 3</time_frame>
    <description>above grade 3 AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS rate</measure>
    <time_frame>From the start of treatment to 9 months</time_frame>
    <description>9-month-overall survival rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs+SAEs</measure>
    <time_frame>from the first drug administration to within 90 days for the last SHR-1701 dose</time_frame>
    <description>Adverse Events and Serious Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to approximately 6 months</time_frame>
    <description>Progression-Free-Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>Up to approximately 12 months</time_frame>
    <description>Disease Control Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to 2 years</time_frame>
    <description>OS is the time interval from the start of treatment to death due to any reason or lost of follow-up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>SHR-1701</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1701</intervention_name>
    <description>PDL1/TGFβ</description>
    <arm_group_label>SHR-1701</arm_group_label>
    <other_name>Gemcitabine and Albumin Paclitaxel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects aged between 18 and 70 years;&#xD;
&#xD;
          -  Life expectancy ≥ 12 weeks judged by the investigator.&#xD;
&#xD;
          -  The ECOG performance status was 0-1.&#xD;
&#xD;
          -  At least 1 measurable lesion conforming to RECIST 1.1 criteria.&#xD;
&#xD;
          -  In subjects with histologically or cytologically confirmed pancreatic cancer, there&#xD;
             was evidence of inoperable locally advanced or distant metastases.&#xD;
&#xD;
          -  Adequate organ and bone marrow function.&#xD;
&#xD;
          -  Female subjects of childbearing age must undergo a serum pregnancy test within 7 days&#xD;
             before the commencement of the study and the results are negative, and are willing to&#xD;
             use a medically approved high potency contraceptive method during the study period and&#xD;
             within 3 months after the last administration of the study drug; For male subjects&#xD;
             whose partner is a female of childbearing age, they should be surgically sterilized or&#xD;
             agree to use an effective method of contraception during the study period and for 3&#xD;
             months after administration of the last study.&#xD;
&#xD;
          -  Willing to consent and signed the informed consent, and able comply with the planned&#xD;
             visit, research treatment, laboratory examination and other test procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to the study drug or any of its excipients; Or had a serious allergic&#xD;
             reaction to other monoclonal antibodies.&#xD;
&#xD;
          -  Previous exposure to drugs/antibodies acting on T cell co-stimulation or checkpoint&#xD;
             pathways.&#xD;
&#xD;
          -  Major surgery within 28 days before the first experimental treatment (biopsy required&#xD;
             for diagnosis is permitted).&#xD;
&#xD;
          -  Subject with central nervous system (CNS) metastases.&#xD;
&#xD;
          -  Had other active malignant tumors within 5 years before entering the study. Except for&#xD;
             basal cell or squamous cell carcinomas, superficial bladder carcinomas, carcinoma in&#xD;
             situ of the cervix, ductal carcinoma in situ, and papillary carcinoma of the thyroid,&#xD;
             which may be treated locally and have been cured.&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency&#xD;
             syndrome (AIDS), untreated active hepatitis.&#xD;
&#xD;
          -  The presence of clinically significant acute or chronic pancreatitis.&#xD;
&#xD;
          -  The presence of other acute or chronic infections of clinically significant&#xD;
             significance.&#xD;
&#xD;
          -  History of allogeneic organ transplantation or allogeneic hematopoietic stem cell&#xD;
             transplantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>September 26, 2021</last_update_submitted>
  <last_update_submitted_qc>September 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

